Subscribe to Money Morning get daily headlines subscribe now! Money Morning Private Briefing today's private briefing Access Your Profit Alerts

We Know a Good Deal When We See One

In a brand new research report, Zacks Equity Research gave kudos to Wedbush Securities analysts Gregory R. Wade, David M. Nierengarten and Christopher N. Marai for their early "Buy" alert on blood-cancer biotech Pharmacyclics Inc. (Nasdaq: PCYC).

The trio of PhD analysts has been covering the Sunnyvale-based Pharmacyclics for more than a year, Zacks noted. In March, when the stock was trading at $86, they raised their 12-month price target from $110 to $165.

Leave a Reply

Your email address will not be published. Required fields are marked *

Some HTML is OK